Risk Factors for Colistin-Associated Acute Kidney Injury: A Multicenter Study from Turkey

Japanese Journal of Infectious Diseases

Birgul Kacmaz¹  Dogan Baris Ozturk⁴  Serdar Gul¹  Ferit Kuscu³  Hande Aydemir⁵  Emel Aslan⁶  Ozcan Deveci⁶  Ferda Yaman⁷  Fazilet Duygu² 

[1] Department of Infectious Diseases and Clinical Microbiology, Kirikkale University;Department of Infectious Diseases and Clinical Microbiology, Gaziosmanpasa University;Department of Infectious Diseases and Clinical Microbiology, Numune Educational and Research Hospital;Department of Infectious Diseases and Clinical Microbiology, Ulucanlar Eye Educational and Research Hospital;Department of Infectious Diseases and Clinical Microbiology, Bulent Ecevit University;Department of Infectious Diseases and Clinical Microbiology, Dicle University;Department of Anesthesiology and Reanimation, Kirikkale University

关键词: colistin;    acute kidney injury;    risk factors;   

DOI  :  10.7883/yoken.JJID.2014.501

学科分类：传染病学

来源: National Institute of Infectious Diseases

【 摘 要 】

References(29)The aim of this study was to investigate the incidence of acute kidney injury (AKI) and risk factors due to colistin use in patients infected with multidrug-resistant pathogens. This multicenter, retrospective, observational study was conducted in Turkey, at 5 different research and university hospitals. Cox regression analyses were performed, to determine independent predictors of AKI. From April 2012 to July 2014, a total of 216 patients aged between 18–94 years, treated with colistimethate sodium (CMS) were included in the study. The mean age of the patients was 60.3 ± 20.1 years. The overall incidence of AKI was 34.3% (74/216) at any time during treatment. Concomitant use of loop diuretics, baseline creatinine level, and CMS dosage were independently associated with AKI. According to our results, patients with higher baseline creatinine levels, or patients who had to use concomitant loop diuretics may need to be monitored more closely, and dose adjustment should be done promptly. More comprehensive studies are, however, still needed to evaluate the efficacy of low-dose colistin since higher doses tend to increase the risk of AKI.

【 授权许可】

Unknown